Rick Gonzalez, AbbVie CEO (Pablo Martinez Monsivais/AP Images)
AbbVie tosses its triplet therapy for cystic fibrosis, leaving Vertex to reign supreme
AbbVie went all in on cystic fibrosis a few years ago, shelling out $245 million for a portfolio of drugs from Galapagos in the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
